BioPorto Diagnostics is pleased to announce the launch of our first-in class NGAL monkey antibody portfolio

March 2014

The launch of NGAL Monkey antibodies is yet another step in our continued efforts to raise the focus on nephrotoxicity in drug discovery, and it makes our range on kidney related antibodies the most comprehensive on the market.

 About NGAL Monkey antibodies 

The NGAL monkey antibodies reacts with NGAL from cynomolgus (Macaca fascicularis) and rhesus (Macaca mulatta) and can be used in a variety of different applications. Monkey NGAL, which by analogy with its homologues in other mammalian species, is released from activated neutrophils in inflammation or infection, from certain epithelial cancers, and more dramatically from renal tubular cells in response to ischemic or nephrotoxic injury.
The monkey or non-human primate (NHP) is an important experimental model for medical research because of its close resemblance to the human physiology, and emphasizes our outstanding focus on renal injury and nephrotoxicity through all stages of drug discovery and clinical research.

The antibodies have been evaluated by the PSTC and a report has been published: PSTC Report